Supernus Pharmaceuticals SUPN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's total equity?
- Supernus Pharmaceuticals (SUPN) reported total equity of $1.08B in Q1 2026.
- How has Supernus Pharmaceuticals's total equity changed year-over-year?
- Supernus Pharmaceuticals's total equity increased by 4.5% year-over-year, from $1.03B to $1.08B.
- What is the long-term trend for Supernus Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total equity has grown at a 7.3% compound annual growth rate (CAGR), from $744.86M to $1.06B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.